THE CANNABINOID EXPERTS
MIND Bioscience is a Cannabis Tech Company delivering innovative cannabinoids for breakthrough therapies based on cannabinoid receptor pharmacology. Unique in both Europe and the USA, MIND Bioscience is a successful combination of biotechnology, chemistry and bioinformatics.
MIND Biosience will become Europe’s leading cannabis tech company supplying all cannabinoids for research, clinics and application in food, cosmetics and pharma.
Being the first point of contact for economic opportunities in cannabinoid drug discovery, from understanding the cannabinoid science to streamlining all processes from biotech to drug discovery
Dimitrios received his PhD from the University of California, San Diego (UCSD). In addition, he completed a Master of Science in Chemistry from the University of Chicago and a Master of Science in Biochemistry from Ball State University in Muncie, Indiana, USA. In 1998 he completed a postdoc in Marburg and afterwards he founded Taros Chemicals GmbH & Co. KG, one of Europe‘s leading chemical CRO companies. Since Taros’ Inception, Dimitrios has been an active player on the European biotech scene and a serial (co) founder of biotechnology companies. He is the author of 18 publications and holds 4 patents. Dimitrios played a leading role in establishing the world’s largest publicly funded drug identification platform. The European Lead Factory (ELF) is a pan-European consortium of 30 cooperation partners from the commercial sector and academia, with a total investment of EUR 196 million. As a member of the Project Executive Board and the Project Management Team, Dimitrios ensured that the project received a subsequent funding round of 5 years.
Oliver studied pharmacy in Münster and has been working on the biosynthesis and analysis of natural plant substances since receiving his PhD. He was a professor at the University of Groningen, NL, and now holds the Chair of Technical Biochemistry at the TU Dortmund University. Since 2003 his research topic has been the biosynthesis of cannabinoids and the heterologous biosynthesis of THC. He is the author of more than 250 publications, reviews and book chapters. Oliver has already worked in the past on 2 third-party funded projects (AiF, DBU) that dealt with the fundamental clarification of cannabinoid biosynthesis. He advises companies on cannabis legalization and founded the company Ion-Gas in 2014, which sells IMS spectrometers for the detection of cannabis metabolites in the breath. This company was successfully brought onto the market from 2012 to 2014 with an Exist grant. A VIPplus application with a volume of 1.7 million euros has currently been applied for.
Alexander received his PhD in 1999 from the University of Göttingen on the total synthesis of natural products for the use in antibiotic research. He joined Taros Chemicals GmbH & Co. KG in 2000 as laboratory manager and supervised a wide variety of syntheses, which were primarily commissioned by companies in the pharmaceutical, agricultural, cosmetic and application chemicals sectors. The main focus of the work was on medicinal-chemical projects with extensive scaffold syntheses. In 2004 Alex was appointed as managing director of Taros Chemicals. In addition to his management activities, he was active as a project manager for Taros in a wide variety of publicly funded consortia, which mainly focused on biotechnological research. Furthermore, he was in charge of developing a proprietary project management and laboratory journal software which controls all relevant chemical and commercial processes in-house on a web-based basis (TarosGate®).
